A Study of the Co-administration of Sitagliptin and Atorvastatin in Inadequately Controlled Type 2 Diabetes Mellitus (MK-0431E-211 AM1)

Inclusion Criteria:

- has type 2 diabetes mellitus

- is a male, or a female who is highly unlikely to conceive

- is currently on monotherapy with metformin (at least 1500 mg/day) for at least 8
weeks

- is not on statin therapy or other lipid-lowering agents for at least 6 weeks

Exclusion Criteria:

- has a history of type 1 diabetes mellitus, ketoacidosis or possibly has type 1
diabetes

- has ever taken a dipeptidyl peptidase IV inhibitor (such as sitagliptin,
vildagliptin, alogliptin, or saxagliptin) or a glucagon-like peptide-1 mimetic (such
as exenatide or liraglutide), or has required insulin therapy within 12 weeks prior
to signing informed consent

- has been on a peroxisome proliferator-activated receptor gamma agonist within the
prior 12 weeks

- has been treated with a statin or other lipid-lowering agents, including over the
counter supplements of fish oils within 6 weeks

- intends to consume at least 1.2 liters of grapefruit juice per day during the course
of the study

- is on or is likely to require treatment with 14 consecutive days or more, or repeated
courses of corticosteroids

- is on a weight loss program and not in the maintenance phase or has started a weight
loss medication (such as orlistat or sibutramine) within the prior 8 weeks

- has undergone a surgical procedure within the prior 4 weeks

- has a history of myopathy or rhabdomyolysis with any statin.

- has cardiovascular disease

- has New York Heart Association (NYHA) Class III or IV congestive heart failure,
inadequately controlled hypertension, a medical history of active liver disease,
chronic progressive neuromuscular disorder, is HIV positive, has a clinically
significant hematological disorder, uncontrolled endocrine or metabolic disease known
to influence glycemic control or serum lipids/lipoproteins, untreated hyperthyroidism
or is currently under treatment for hyperthyroidism

- has a history of malignancy within 5 years, except for adequately treated basal cell
or squamous cell skin cancer or in situ cervical cancer

- is pregnant or breastfeeding, or is intending to become pregnant or donate eggs
within the projected duration of the study and post-study follow-up period

- uses recreational or illicit drugs or has had a recent history (within the last year)
of drug abuse or increased alcohol consumption